---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008301"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:13:29.390869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M

## Summary
- Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.
- Net loss Q4 2022: $2.5M ($0.24 per share) vs $3.9M ($0.41) in Q4 2021; Adjusted EBITDA improved to ($0.065M) from ($1.6M).
- Installed ten ALLY Adaptive Cataract Treatment Systems in 2022; contracts signed for six more systems, installations expected H1 2023.
- SG&A expenses rose 24% to $7.2M, driven by ALLY promotion; R&D fell 53% to $1.6M as ALLY development costs normalized.
- CEO reports positive surgeon feedback: ALLY cuts 1-1.5 hours from surgical day, supports faster case volume.

## SEC filing metadata
- accession: 0000950170-23-008301
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/0000950170-23-008301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/lnsr-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008301
- JSON: https://secwatch.observer/filing/0000950170-23-008301.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008301.txt

## Key facts
- Earnings Releases
  LENSAR, Inc. reported the quarter ended December 31, 2022 results: revenue $10.2 million, net income $2.5 million, or ($0.24) per share, EPS ($0.24) per share.
  - Period: the quarter ended December 31, 2022
  - Revenue: $10.2 million
  - Net income: $2.5 million, or ($0.24) per share
  - EPS: ($0.24) per share
  - Result: reported results
  source text: and so accurate that I have added at least 3 to 4 cases onto my surgery days." Fourth Quarter 2022 Financial Results Total revenue for the quarter ended December 31, 2022 was $10.2 million, a decrease of $1.0 million, or 9%, compared to total revenue of $11.2 million for the quarter ended December 31, 2021. The decrease from the fourth quarter of 2021 was primarily
  evidence_url: https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/0000950170-23-008301-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.